Conference call and webcast today at 4:30 p.m. ET

Read the original:
Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Global News Feed Comments Off on Otonomy Reports Third Quarter 2020 Financial Results and Provides Corporate Update | November 5th, 2020

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights.

Excerpt from:
Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

Global News Feed Comments Off on Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights | November 5th, 2020

WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent developments in its business.

View original post here:
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

Global News Feed Comments Off on Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update | November 5th, 2020

-- Interim data from Phase 2 study showed that once-weekly formulation of setmelanotide achieved safety and efficacy results comparable to daily-dosing formulation ---- Additional data from long-term extension study in POMC deficiency obesity showed durable weight loss and reductions in hunger at up to three years on therapy ---- Setmelanotide was generally well tolerated --BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced new clinical data for setmelanotide, its investigational melanocortin-4 receptor (MC4R) agonist, being presented at The Obesity Society’s ObesityWeek® 2020, held virtually from November 2-6, 2020.

See the rest here:
Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

Global News Feed Comments Off on Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 | November 5th, 2020

PALO ALTO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on November 1, 2020, the compensation committee of BridgeBio’s board of directors granted three new employees restricted stock units for an aggregate of 9,566 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

Read more:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Global News Feed Comments Off on BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | November 5th, 2020

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. Jeff had previously been appointed as interim CEO in May 2020 while continuing to serve on the Board of Directors.

Link:
BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO

Global News Feed Comments Off on BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO | November 5th, 2020

SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported third quarter 2020 financial results.

More:
Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update

Global News Feed Comments Off on Oncternal Announces Third Quarter 2020 Financial Results and Provides Business Update | November 5th, 2020

PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

Visit link:
10x Genomics to Participate in the Stifel 2020 Healthcare Conference

Global News Feed Comments Off on 10x Genomics to Participate in the Stifel 2020 Healthcare Conference | November 5th, 2020

The rest is here:
ObsEva Announces Third Quarter 2020 Financial Results and Business Update

Global News Feed Comments Off on ObsEva Announces Third Quarter 2020 Financial Results and Business Update | November 5th, 2020

Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo. Synovitis was assessed using an advanced and sensitive imaging technique called Power Doppler ultrasonography (PDUS). These data are being presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting, November 5-9, 2020.

See the article here:
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Global News Feed Comments Off on Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study | November 5th, 2020

IMPORTANT EVENTS DURING THE THIRD QUARTERTasquinimod

Read more here:
Active Biotech Interim report January – September 2020

Global News Feed Comments Off on Active Biotech Interim report January – September 2020 | November 5th, 2020

Researchers discuss the development and potential of stem cellbased therapies in the treatment of Parkinson disease.

In assessing treatment for Parkinson disease (PD), the current standard of care involves levodopa, potentially in combination with carbidopa, to address the loss of dopamine known to occur as the condition progresses. However, several innovations in therapy for PD have occurred in recent years, particularly deep brain stimulation and the potential use of stem cells.

Discussing in a review published in International Journal of Molecular Sciences, researchers Zhaohui Liu, PhD, MSc, and Hoi-Hung Cheung, PhD, sought to discuss the development of new therapeutic strategies that have led to the initiation of exploratory clinical trials, particularly the application of stem cells for the treatment of PD.

Delving into the use of stem cellbased treatments in PD, the researchers say that several important pathways have emerged as targets for potential therapeutic intervention.

Conventional therapeutic strategies for relieving the symptomatic stages of PD remain, but with new genetic insights, it may be possible to use preventive neuroprotective treatments for people at risk of developing PD, they highlight. In parallel with efforts to prevent and control symptomatic PD, researchers are also investigating stem cells as replacements for diseased neurons or degenerated tissues.

As they note, dopaminergic (DA) cell transplantation is believed to be the most promising cell replacement therapy. Aligned with this approach, a recent novel treatment showcased the plausibility of reprogramming the skin cells of a single patient with PD to take on the characteristics of DA neurons and replace damaged brain cells. In their findings, the patient exhibited improvements in quality of life and day-to-day activities requiring motor skills. However, as this treatment was performed on only 1 person, the researchers cautioned that larger, diverse clinical studies are needed to demonstrate further efficacy and long-term results.

Other notable stem cellbased treatments include:

Although we are not yet examining a disease-modifying treatment, stem cell transplantation has the potential to be at the forefront of such PD treatments in the future, conclude the researchers. The transplantation process and the procedures required for its optimization are still not fully understood, and further research is required to achieve treatment for PD.

Reference

Liu Z, Cheung H-H. Stem cell-based therapies for Parkinson disease. Int J Mol Sci. Published online October 29, 2020. doi:10.3390/ijms21218060

See the original post:
A Review of Stem CellBased Therapies for Parkinson Disease - AJMC.com Managed Markets Network

Skin Stem Cells Comments Off on A Review of Stem CellBased Therapies for Parkinson Disease – AJMC.com Managed Markets Network | November 5th, 2020

You most likely have noticed this phenomenon. When someone you know gets critically injured, experiences a serious illness or a major stressor, they soon look older. Sound familiar? Next time you see your friend, their hair is gray or even white. Have you ever wondered why that happens?

A new study from scientists at Harvard now reveals our sympathetic nervous system likely plays a major role in this process. The sympathetic nervous system is also called the fight or flight system. When youre in a stressful or dangerous situation, the sympathetic nervous system releases hormones to increase your alert level and heart rate to prepare you to act.

It all starts in a small area of the brain called the amygdala, and it eventually activates adrenal glands in the kidneys, which release adrenaline to coordinate the response of your internal organs and heighten your mental focus.

We have stem cells in the bottom of each hair follicle. These stem cells mature into cells called melanocytes, which produce pigment for our hair and skin color. Using mice, researchers found stressful events can lead to damage in the stem cells in our hair follicles.

Stress caused these stem cells to mature much faster than normal, which meant the supply of stem cells in the hair follicles eventually ran out. Without the stem cells producing melanocytes, the hair in the follicle lost its color and looked gray.

But how did this happen? The researchers thought maybe the immune system attacked these melanocytes resulting in the graying or that a hormone called cortisol produced by the adrenal glands might be responsible. Neither of those turned out to be the cause of the graying hair.

In some intricate experiments, the scientists discovered sympathetic nerve cells associated with hair follicles were the key. These nerve cells released a hormone called noradrenaline into the melanocyte stem cells, which caused them to mature and eventually disappear from the base of the follicle and caused the graying of the hair.

In other experiments, noradrenaline treatment of human melanocytes in lab cultures lead to rapid growth, suggesting this same process likely occurs in humans leading to the graying of hair.

Other scientists also have shown depleting melanocytes leads to a progression of the first gray hairs to gray and then to white fur in dark-colored mice, which sounds like what we see in humans.

So heres a question: If you have rapid growth of these melanocytes, can you prevent the hair from graying? The answer appears to be yes, based on the treatment of these same mice with drugs that block the release of noradrenaline.

This treatment couldnt be used in humans because blocking the flight or flight response would have severe consequences in other areas of our lives. But this new information could be used in the future for more specific drugs that would just work on the hair follicles. This would be a great benefit to me if I only had enough hair.

Medical Discovery News is hosted by professors Norbert Herzog at Quinnipiac University, and David Niesel of the University of Texas Medical Branch. Learn more at http://www.medicaldiscoverynews.com.

View original post here:
Research providing better understand of graying hair | Health - Galveston County Daily News

Skin Stem Cells Comments Off on Research providing better understand of graying hair | Health – Galveston County Daily News | November 5th, 2020

The latest research report on the Anti-Ageing Drugs Market Industry Analysis, Market Size, Opportunities and Forecast, 2020 2028 provides a comprehensive assessment of the Anti-Ageing Drugs market for the forecast period from 2020 to 2028, including market values for the years 2018 and 2019. The investigative report provides a detailed analysis of the impact of COVID-19 on various segments in the Anti-Ageing Drugs market based on product type, application, and end-use across numerous countries around the world. Further, the report also provides insights into market developments, trends, supply and demand changes across various regions across the globe. Thereby, the report provides a holistic view on the Anti-Ageing Drugs Market in order to help decision makers with various strategic insights and future outlook. The Anti-Ageing Drugs market is expected to witness continued growth during the forecast period from 2020 to 2028.

Leading companies reviewed in the Anti-Ageing Drugs Market report are: La Roche-Posay, Revision Optics, Calico, Nu Skin, LORAL, Unity Biotechnology

Get Free Exclusive Sample of this Premium Report at: https://www.zealinsider.com/report/6400/anti-ageing-drugs-market#sample

The report covers various aspects of the Anti-Ageing Drugs market segmented into product type, application and end-use. The report provides market numbers for the years 2018 and 2019 based on actual market findings also market estimates for forecasts for the period from 2020 to 2020 for each of the products types, applications and end-use segments.

Furthermore, the report includes a detailed competitive analysis among the market participants in the Anti-Ageing Drugs market. The report offers an in-depth comparative analysis of the competitors in the market based on their product offerings, market share and geographic presence. Some of the leading companies covered in the report include La Roche-Posay, Revision Optics, Calico, Nu Skin, LORAL, Unity Biotechnology

***NOTE***

We are continuously monitoring the market developments and changes occurring as a direct or indirect impact of the ongoing COVID-19 pandemic. Thereby, we are in a position to provide information on the market values and trends for both pre-COVID-19 and post-COVID-19 scenarios.

Target audiences for the report include:

Anti-Ageing Drugs Market Segmentation, By Product Type:Serums and supplements, Antioxidants and enzymes, Stem cells and drugs

Anti-Ageing Drugs Market Segmentation, By Application:Skin and hair, Skeletal and muscles, Age-related disorders, Others

Anti-Ageing Drugs Market Segmentation, By Geography:

Access Full Report information, here: https://www.zealinsider.com/report/6400/anti-ageing-drugs-market

Key Focus Areas in the Report:

Go here to read the rest:
Global Anti-Ageing Drugs Market (2020) to Witness Huge Growth by 2026 | La Roche-Posay, Revision Optics, Calico, Nu Skin, L'ORAL, Unity Biotechnology,...

Skin Stem Cells Comments Off on Global Anti-Ageing Drugs Market (2020) to Witness Huge Growth by 2026 | La Roche-Posay, Revision Optics, Calico, Nu Skin, L’ORAL, Unity Biotechnology,… | November 5th, 2020

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market grew at a CAGR of around 16% during 2014-2019. Looking forward, the publisher expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a branch of biomedical sciences aimed at restoring the structure and function of damaged tissues and organs. It involves the utilization of stem cells that are developed in laboratories and further implanted safely into the body for the regeneration of damaged bones, cartilage, blood vessels and organs. Cellular and acellular regenerative medicines are commonly used in various clinical therapeutic procedures, including cell, immunomodulation and tissue engineering therapies. They hold potential for the effective treatment of various chronic diseases, such as Alzheimer's, Parkinson's and cardiovascular disorders (CVDs), osteoporosis and spinal cord injuries.

The increasing prevalence of chronic medical ailments and genetic disorders across the globe is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is prone to various musculoskeletal, phonological, dermatological and cardiological disorders, is stimulating the market growth. In line with this, widespread adoption of organ transplantation is also contributing to the market growth. Regenerative medicine minimizes the risk of organ rejection by the body post-transplant and enhances the recovery speed of the patient.

Additionally, various technological advancements in cell-based therapies, such as the development of 3D bioprinting techniques and the adoption of artificial intelligence (AI) in the production of regenerative medicines, are acting as other growth-inducing factors. These advancements also aid in conducting efficient dermatological grafting procedures to treat chronic burns, bone defects and wounds on the skin. Other factors, including extensive research and development (R&D) activities in the field of medical sciences, along with improving healthcare infrastructure, are anticipated to drive the market further.

Companies Mentioned

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Regenerative Medicine Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Type

6.1 Stem Cell Therapy

6.1.1 Market Trends

6.1.2 Market Forecast

6.2 Biomaterial

6.2.1 Market Trends

6.2.2 Market Forecast

6.3 Tissue Engineering

6.3.1 Market Trends

6.3.2 Market Forecast

6.4 Others

6.4.1 Market Trends

6.4.2 Market Forecast

7 Market Breakup by Application

7.1 Bone Graft Substitutes

7.1.1 Market Trends

7.1.2 Market Forecast

7.2 Osteoarticular Diseases

7.2.1 Market Trends

7.2.2 Market Forecast

7.3 Dermatology

7.3.1 Market Trends

7.3.2 Market Forecast

7.4 Cardiovascular

7.4.1 Market Trends

7.4.2 Market Forecast

7.5 Central Nervous System

7.5.1 Market Trends

7.5.2 Market Forecast

7.6 Others

7.6.1 Market Trends

7.6.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals

8.1.1 Market Trends

8.1.2 Market Forecast

8.2 Specialty Clinics

8.2.1 Market Trends

8.2.2 Market Forecast

8.3 Others

8.3.1 Market Trends

8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America

9.2 Asia Pacific

9.3 Europe

9.4 Latin America

9.5 Middle East and Africa

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/erd0e3

Go here to see the original:
Global Regenerative Medicine Market (2020 to 2025) - Industry Trends, Share, Size, Growth, Opportunity and Forecast - ResearchAndMarkets.com -...

Spinal Cord Stem Cells Comments Off on Global Regenerative Medicine Market (2020 to 2025) – Industry Trends, Share, Size, Growth, Opportunity and Forecast – ResearchAndMarkets.com -… | November 5th, 2020

Share on PinterestPhotography by Gabriela Hasbun

We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Heres our process.

Gommage is a French exfoliation technique thats been gaining popularity in the United States. The word gommage literally translates to erasing or exfoliation.

The concept of exfoliation isnt new in France. Marie Antoinette supposedly used a mask made of cognac, eggs, powdered milk, and lemon juice to cleanse and exfoliate her skin while ruling France in the 1700s.

Modern gommage uses a combination of ingredients that exfoliate your skin chemically through the combination of enzymes and scrubbing. Along with other exfoliating techniques, it has the potential to clear away dead skin cells and stimulate skin cell growth to keep your skin looking polished and smooth.

Keep reading to find out how gommage exfoliation works, why you may want to include it in your skin care routine, and who makes a good candidate.

Gommage products contain one of several enzymes that have proteolytic effects on dead skin cells. Proteolytic simply means they break down the proteins that make up these cells so that they can easily be removed.

The enzymes found in gommage products can be extracted from plant or animal sources. Some of the most commonly used enzymes include:

Gommage exfoliants also contain sticky ingredients like xanthan gum or paraffin that mechanically exfoliate your skin by pulling away dead skin cells when the product is removed from your skin.

When performing a gommage treatment at home, you can follow the instructions on the package. Most products will instruct you to:

Exfoliants are usually divided into two categories:

There are many types of exfoliation techniques, ranging from homemade scrubs to chemical peels. Most exfoliation products work by exfoliating your skin either mechanically or chemically, but gommage products do both when applied through gentle massage.

Theres no research available specifically comparing gommage products with other exfoliant techniques, but many products claim to be gentler on your skin than other exfoliants. Gommage formulas vary widely among products so some of these products are gentler and more effective than others.

Gommage exfoliants have the potential to have the same benefits as traditional exfoliating techniques, such as:

No matter what type of product youre using, over-exfoliating can lead to skin thats:

Gommage exfoliants often use plant-sourced enzymes in their formulas. If you have a known allergy to any fruits or plants, you may want to check the ingredients carefully before using a gommage product. Pineapples, papayas, and pumpkin are three common plants often used in these products.

Any time you start using a new skin care product, its a good idea to use it on only a small part of your skin to see how your body reacts before applying to your face or other sensitive areas.

Gommage products are gentle enough to be used by most adults. People with naturally oily skin can exfoliant as often as every day. If you have drier skin, you may only need to exfoliate once per week.

Gommage products are often marketed as gentler alternatives to traditional exfoliants. However, formulas vary among brands. If you have very sensitive skin, you may want to stick to a washcloth and mild chemical exfoliator.

If you have acne or are taking retinol or benzoyl peroxide for acne, its a good idea to talk to a dermatologist before using exfoliants since they can lead to worse breakouts

Its also a good idea to talk to a dermatologist if your skin is thinning, you have open wounds, or you have another skin condition you think could be affected.

Some aestheticians in your area may offer gommage treatments. You can also buy gommage exfoliants at some pharmacies and other places that sell cosmetics.

Shop for gommage exfoliants online.

Gommage comes from the French word for erasing. Gommage treatment involves applying a cream or paste to your skin and waiting for it to dry. As the product hardens, enzymes in the product break down dead skin cells. When you rub the product away, the friction rubs these dead skin cells away.

Gommage exfoliation is relatively safe and may be a good option if youre looking for a gentle exfoliant. Whenever you start using a new skin care product, its a good idea to use it on a small patch of skin before using it on your entire face to see how your body reacts first.

See the original post here:
Gommage (Gentle Exfoliation) Benefits, Precautions, and How to Do It - Healthline

Skin Stem Cells Comments Off on Gommage (Gentle Exfoliation) Benefits, Precautions, and How to Do It – Healthline | November 3rd, 2020

"It also hydrates and plumps up collagen making the skin appear more luminous." Go hard on it.

Retinol

You'll also need to have an exfoliant in your routine. We're talking chemical exfoliants, like retinol (can be in the form of a serum or cream - whatever works).

"Retinol (vitamin A) helps to improve cellular turnover, so that melanin patches are reduced in colour and some pigment may also be permanently shed too," said Dr D'Anna.

If retinol doesn't agree with your skin at this stage, try lactic acid or glycolic acid (again - can be used in a cleanser, toner, serum etc). These will do the job, too.

SPF

Okay. This is less of an option, and more of awe're-telling-you-to-do-it thing. Even Dr D'Anna agreed: "SPF is mandatory in reducing the darkening of the spots. Without the sun, the amount of melanin produced is very low."

"Prevention is much better than treatment. So, wear SPF every day, and cover your arms/hands and head/face with a good hat or long sleeves," added Dr D'Anna.

Prescription skincare

If all else fails on the skincare front - see your doctor for other topicaloptions.

"There are some pharmaceuticals that may be prescribed by your doctor too to help reduce the pigmentation," said Dr D'Anna. "This needs to be done under medical guidance and care to ensure that the skin has been examined and then diagnosed correctly."

Maybe. But you need to check in with a dermatologist or skin specialist first to make sure your skin type can be safely treated.

Dr D'Anna said, "The best treatment will vary according to your skin, the level of pigmentation and other skin considerations. It is best to get the advice of a qualified dermal therapist before proceeding."

Here are some professional treatments that can help reduce these melanin pigmentation patches:

Laser or IPL

These are good non-invasive solutions that will usually give you significant results after a course of treatments.

"A combination of topical treatments, light and laser therapies work best," said Dr Gunatheesa. "Broad-based light therapy, fractional ablative lasers will fade or remove existing liver spots."

Okay. How does that work?

"Laser or IPL also reduce the amount of colour in the skin," said Dr D'Anna. "The light energy heats the damaged and pigmented patches, so that the pigment is disrupted and lightened over a series of sessions."

Here is the original post:
Here's how to treat those brown spots on your face, chest and hands. - Mamamia

Skin Stem Cells Comments Off on Here’s how to treat those brown spots on your face, chest and hands. – Mamamia | November 3rd, 2020

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Jefferies Virtual London Healthcare Conference. The presentation is scheduled for 6:45 – 7:15am ET on Tuesday, November 17, 2020 and will be webcast.

Original post:
Checkmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare Conference

Global News Feed Comments Off on Checkmate Pharmaceuticals to Present at the Upcoming Jefferies Virtual London Healthcare Conference | November 3rd, 2020

COPENHAGEN, Denmark, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases.

See the article here:
Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases

Global News Feed Comments Off on Ascendis Pharma A/S Appoints Dr. Mark A. Bach as Senior Vice President of Clinical Development and Medical Affairs for Endocrinology Rare Diseases | November 3rd, 2020

CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today announced that the Company has initiated the first U.S. Phase 3 clinical trial studying nabiximols for multiple sclerosis (MS)-associated spasticity. Nabiximols, known as Sativex® outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts of the cannabis plant administered as an oral spray. Positive results from three previous European Phase 3 clinical studies show nabiximols was well-tolerated and provided continued reductions in patient-reported spasticity for individuals with MS.

Link:
GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity

Global News Feed Comments Off on GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity | November 3rd, 2020